Startups
RocketVax AG is a Swiss biotech startup based in Basel and was established in 2020. The company has its foundation in the ties between Swiss Rockets AG, a Swiss incubator and accelerator for startups, Gigabases Switzerland AG, a spinoff of ETH Zurich, and a team of expert scientists from the University of Basel, the University of Zurich, the ETH Zurich, the University Hospital Basel and the Swiss Tropical and Public Health Institute in Basel.
At RocketVax, we use proprietary molecular biology and chemical technology to develop novel vaccines. Our first product is RVX-13, a live, single-cycle vaccine against SARS-CoV-2, which is based on breakthrough genetic engineering. Leading Swiss expert scientists from immunology and virology have joined forces to translate a novel development concept against the SARS-CoV-2 virus, a pathogen that has already impacted countless lives worldwide, into a vaccine of the next generation.
At RocketVax, we use proprietary molecular biology and chemical technology to develop novel vaccines. Our first product is RVX-13, a live, single-cycle vaccine against SARS-CoV-2, which is based on breakthrough genetic engineering. Leading Swiss expert scientists from immunology and virology have joined forces to translate a novel development concept against the SARS-CoV-2 virus, a pathogen that has already impacted countless lives worldwide, into a vaccine of the next generation.
Overview
Location
Switzerland, Basel-City, Basel
Employees
11-50
Total raised
$7.95M
Founded date
2020
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 14, 2025 | Swiss Rockets obtains strategic investment | Rocketvax Ltd one of Switzerland’s next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies. One of Rocketvax’s leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has demonstrat... |
| Nov 27, 2023 | Sparks IPO Academy prepares new cohort for next move | |
| Feb 7, 2023 | Fresh funds for RocketVax to accelerate second generation COVID-19 vaccines | |
| Mar 18, 2022 | Researchers accelerate two SARS-Cov-2 vaccine candidates into clinical trials | |
| Aug 9, 2021 | This Swiss biotech startup is developing a new Covid-19 vaccine; raises €6.6M to prepare clinical trials | Vaccines and antibiotics continue to revolutionise our ability to prevent diseases, improve health and save lives. According to WHO (World Health Organisation), vaccines represent one of the most significant strides in medicine. With techno... |
| Aug 5, 2021 | RocketVax raises CHF 7.2 million to advance clinical studies for its COVID-19 vaccine | Rocketvax’s seed investment stems from multiple sources. These include CHF 1.2 million from a research grant from Innosuisse, CHF 1.0 million from the Canton of Basel-Stadt, CHF 1.0 million from the University Hospital Basel. Private invest... |
| Jun 21, 2021 | Encouraging progress of COVID-19 solutions from Switzerland | CHF 1 million for a next-generation vaccine The University Hospital Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research collaboration with the startup company Rock... |
| Jun 21, 2021 | Encouraging progress of COVID-19 solutions from Switzerland |
Reviews 0
FAQ about RocketVax AG
When was RocketVax AG founded?
RocketVax AG was founded in 2020.
How much funding has RocketVax AG raised?
RocketVax AG has raised $7.95M in total across 1 funding round.
What has the press written about RocketVax AG?
Parsers VC has collected 9 articles mentioning RocketVax AG, among them “Swiss Rockets obtains strategic investment” (Mar 14, 2025) and “Sparks IPO Academy prepares new cohort for next move” (Nov 27, 2023).
Is RocketVax AG still active?
Yes, RocketVax AG is active; its latest activity on Parsers VC dates from Aug 5, 2025.